Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Quaise, a US-based precision geothermal drilling technology spinout of Massachusetts Institute of Technology (MIT), has obtained $6m in a seed round led by MIT-aligned tough tech fund and incubator The Engine that also included venture firm Collaborative Fund and private investor Vinod Khosla. Quaise has devised a deep drilling method for extracting geothermal energy produced and stored within the interior of Earth. The technique relies on a gyrotron to produce millimetre-scale electromagnetic waves, facilitating drilling at subterranean depths ranging from 10 to 20 kilometres. Paul Woskov, senior research engineer at MIT, is credited with having invented the technology. The funding will support Quaise’s development, recruitment and collaboration plans. Qkine, a UK-based biomedical protein producer spun out of University of Cambridge, closed a £1.5m ($1.9m) series A round featuring Cambridge Enterprise, the university’s tech transfer office. Parkwalk Advisors, the fund management arm of commercialisation firm IP Group, and Martlet Capital, the corporate venturing arm of aerospace, defence and property group Marshall of Cambridge, both took part in the round alongside O2H Ventures’ Human Health EIS Fund and assorted angel investors. Founded in 2016, Qkine develops and produces bioactive proteins such as recombinant growth factors and cytokines used as the basis for stem cell, organoid and regenerative medicine research. The cash will be used to bolster Qkine’s headcount and scale its operations with the aim of securing international growth of its business. KaloCyte, a US-based artificial blood cell substitute producer allied to University System of Maryland, has secured $300,000 of capital from university venture vehicle Maryland Momentum Fund, Technical.ly reported yesterday. The funding comes ahead of a planned series A round for KaloCyte later this year. KaloCyte is developing an artificial blood product called ErythoMer intended to facilitate transfusions in situations where refrigerated fresh blood is unavailable. The funding will go toward technical development, following an increase in KaloCyte’s staff from two to five. KaloCyte was founded in St. Louis but has since moved headquarters to University of Maryland, Baltimore’s School of Medicine. Elyza, a Japan-based developer of artificial intelligence-equipped retail and natural language processing technologies spun out of University of Tokyo’s Matsuo Lab, has been included in accelerator program Plug and Play Japan’s Brand & Retail division of the summer and autumn 2020 Batch. The incubator provides between $25,000 and $500,000 in funding per company, but it is unclear how much Elyza received. UConn Innovation Fund, the early-stage university venture fund for University of Connecticut, has backed US-based male fertility testing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?